| ￥3500 | |
| Z04767-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized Coagulation factor XI, His, Cynomolgus at 0.5μg/ml (100μl/well) on the plate can bind AntiFactor XI Antibody, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 69.05 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 70-85 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Factor XI (FXI) is the zymogen of a plasma protease (FXIa) that contributes to hemostasis by activating factor IX (FIX). In the original cascade model of coagulation, FXI is converted to FXIa by factor XIIa (FXIIa), a component, along with prekallikrein and high-molecular-weight kininogen (HK), of the plasma kallikrein-kinin system (KKS). |
| Synonyms | FXI; PTA; F11; Coagulation factor XI |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
